Key opportunities in the B-cell inhibitors market for non-oncology diseases include the rising demand for targeted immunomodulatory therapies, driven by increasing autoimmune disorder prevalence.

Type 1 diabetes (T1D) is an autoimmune disease characterized by the immune-mediated destruction of pancreatic B cells. While autoreactive T cells are key ...

B lymphocytes exhibit dual roles in tumorigenesis, acting as both allies and adversaries in the tumor microenvironment (TME). Their anti-tumor functions include recognizing tumor-associated antigens, ...

Chimeric antigen receptor T (CAR-T) cell therapy has emerged as a transformative approach in modern medicine, demonstrating remarkable efficacy in targeting pathogenic B-cell lineages with ...

DESTIN, Fla. — An increasing array of B-cell targeting approaches may aid clinicians in managing the cycles and flares of lupus, according to a speaker at the Congress of Clinical Rheumatology East ...

About five million people worldwide have systemic lupus erythematosus (SLE), an autoimmune disease that damages organs and tissues throughout the body, including skin, joints, kidneys, heart, and ...

Chronic diabetic ulcers represent one of the most challenging complications in modern healthcare, affecting over 131 million people worldwide and generating approximately $755 billion in annual ...